Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases
Neurodegenerative diseases (NDs), such as Alzheimer’s (AD), Parkinson’s (PD), and amyotrophic lateral sclerosis (ALS), share common pathological mechanisms, including metabolism alterations. However, their specific neuronal cell types affected and molecular biomarkers suggest that there are both com...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/9/864 |
| _version_ | 1797484919091363840 |
|---|---|
| author | Débora Lanznaster Giulia Dingeo Rayhanatou Altine Samey Patrick Emond Hélène Blasco |
| author_facet | Débora Lanznaster Giulia Dingeo Rayhanatou Altine Samey Patrick Emond Hélène Blasco |
| author_sort | Débora Lanznaster |
| collection | DOAJ |
| description | Neurodegenerative diseases (NDs), such as Alzheimer’s (AD), Parkinson’s (PD), and amyotrophic lateral sclerosis (ALS), share common pathological mechanisms, including metabolism alterations. However, their specific neuronal cell types affected and molecular biomarkers suggest that there are both common and specific alterations regarding metabolite levels. In this review, we were interested in identifying metabolite alterations that have been reported in preclinical models of NDs and that have also been documented as altered in NDs patients. Such alterations could represent interesting targets for the development of targeted therapy. Importantly, the translation of such findings from preclinical to clinical studies is primordial for the study of possible therapeutic agents. We found that N-acetyl-aspartate (NAA), myo-inositol, and glutamate are commonly altered in the three NDs investigated here. We also found other metabolites commonly altered in both AD and PD. In this review, we discuss the studies reporting such alterations and the possible pathological mechanism underlying them. Finally, we discuss clinical trials that have attempted to develop treatments targeting such alterations. We conclude that the treatment combination of both common and differential alterations would increase the chances of patients having access to efficient treatments for each ND. |
| first_indexed | 2024-03-09T23:11:21Z |
| format | Article |
| id | doaj.art-ffd561e1f1d64cd88008c1b5700afbf9 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T23:11:21Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-ffd561e1f1d64cd88008c1b5700afbf92023-11-23T17:45:02ZengMDPI AGMetabolites2218-19892022-09-0112986410.3390/metabo12090864Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative DiseasesDébora Lanznaster0Giulia Dingeo1Rayhanatou Altine Samey2Patrick Emond3Hélène Blasco4UMR1253, iBrain, INSERM, University of Tours, 37000 Tours, FranceUMR1253, iBrain, INSERM, University of Tours, 37000 Tours, FranceUMR1253, iBrain, INSERM, University of Tours, 37000 Tours, FranceUMR1253, iBrain, INSERM, University of Tours, 37000 Tours, FranceUMR1253, iBrain, INSERM, University of Tours, 37000 Tours, FranceNeurodegenerative diseases (NDs), such as Alzheimer’s (AD), Parkinson’s (PD), and amyotrophic lateral sclerosis (ALS), share common pathological mechanisms, including metabolism alterations. However, their specific neuronal cell types affected and molecular biomarkers suggest that there are both common and specific alterations regarding metabolite levels. In this review, we were interested in identifying metabolite alterations that have been reported in preclinical models of NDs and that have also been documented as altered in NDs patients. Such alterations could represent interesting targets for the development of targeted therapy. Importantly, the translation of such findings from preclinical to clinical studies is primordial for the study of possible therapeutic agents. We found that N-acetyl-aspartate (NAA), myo-inositol, and glutamate are commonly altered in the three NDs investigated here. We also found other metabolites commonly altered in both AD and PD. In this review, we discuss the studies reporting such alterations and the possible pathological mechanism underlying them. Finally, we discuss clinical trials that have attempted to develop treatments targeting such alterations. We conclude that the treatment combination of both common and differential alterations would increase the chances of patients having access to efficient treatments for each ND.https://www.mdpi.com/2218-1989/12/9/864metabolomicsneurodegenerative diseasesglutamatetherapy |
| spellingShingle | Débora Lanznaster Giulia Dingeo Rayhanatou Altine Samey Patrick Emond Hélène Blasco Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases Metabolites metabolomics neurodegenerative diseases glutamate therapy |
| title | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
| title_full | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
| title_fullStr | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
| title_full_unstemmed | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
| title_short | Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases |
| title_sort | metabolomics as a crucial tool to develop new therapeutic strategies for neurodegenerative diseases |
| topic | metabolomics neurodegenerative diseases glutamate therapy |
| url | https://www.mdpi.com/2218-1989/12/9/864 |
| work_keys_str_mv | AT deboralanznaster metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT giuliadingeo metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT rayhanatoualtinesamey metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT patrickemond metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases AT heleneblasco metabolomicsasacrucialtooltodevelopnewtherapeuticstrategiesforneurodegenerativediseases |